Compare ONC & PHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | PHG |
|---|---|---|
| Founded | 2010 | 1891 |
| Country | Switzerland | Netherlands |
| Employees | 12000 | 65340 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 26.1B |
| IPO Year | N/A | N/A |
| Metric | ONC | PHG |
|---|---|---|
| Price | $309.06 | $26.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $385.10 | N/A |
| AVG Volume (30 Days) | 206.8K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $723.76 | $2.93 |
| Revenue Next Year | $15.04 | $4.49 |
| P/E Ratio | $614.06 | ★ $28.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $235.35 | $21.95 |
| 52 Week High | $385.22 | $33.44 |
| Indicator | ONC | PHG |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 50.73 |
| Support Level | $302.26 | $26.44 |
| Resistance Level | $325.40 | $28.19 |
| Average True Range (ATR) | 8.51 | 0.45 |
| MACD | 0.22 | 0.12 |
| Stochastic Oscillator | 59.18 | 68.14 |
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.